Lilly announces details of presentations at the 2024 american society of hematology (ash) annual meeting

Indianapolis , nov. 5, 2024 /prnewswire/ -- eli lilly and company (nyse: lly) today announced that data from studies of jaypirca® (pirtobrutinib), a non-covalent (reversible) bruton's tyrosine kinase (btk) inhibitor, will be presented at the 66th american society of hematology (ash) annual meeting and exposition taking place dec. 7-10 in san diego. in an oral presentation, lilly will report results from the phase 3 bruin cll-321 study, which is evaluating pirtobrutinib versus idelalisib plus rituximab (idelar) or bendamustine plus rituximab (br) in btk inhibitor pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll).
ASH Ratings Summary
ASH Quant Ranking